Month: September 2026

• Independent DSMB reports no safety concerns to date and recommends continuing BriaCell’s pivotal Phase 3 study of Bria-IMT™ plus an immune checkpoint inhibitor
• Seventh consecutive positive DSMB recommendation reinforces the favorable safety and tolerability of BriaCell’s novel immunotherapy approach
• Phase 3 study is being conducted under FDA Fast Track designation, underscoring the substantial unmet need in metastatic breast cancer

PHILADELPHIA and VANCOUVER, British Columbia, Sept. 14, 2026 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, announces that the independent Data Safety Monitoring Board (DSMB) has issued its seventh consecutive positive recommendation following review of clinical data from BriaCell’s pivotal Phase 3 Bria-ABC study of Bria-IMT plus immune checkpoint inhibitor (CPI) in patients with metastatic breast cancer (NCT06072612).

Following its review, the DSMB raised no safety or other clinical concerns and recommended that the study continue without modifications. DSMB meetings occur quarterly in accordance with the study protocol. BriaCell’s ongoing pivotal Phase 3 study is being conducted under Fast Track designation granted by the US Food and Drug Administration (FDA), reflecting the significant unmet medical need in metastatic breast cancer.

“We are very encouraged by the DSMB’s seventh consecutive positive recommendation to continue BriaCell’s pivotal Phase 3 Bria-ABC study,” said Dr. William V. Williams, President and Chief Executive Officer of BriaCell. “This milestone represents continued progress in developing BriaCell’s novel immunotherapies for patients with urgent unmet medical needs.”

About BriaCell Therapeutics Corp.

BriaCell is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. More information is available at https://briacell.com/.

Safe Harbor

This press release contains “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements, including those about the DSMB’s seventh consecutive positive recommendation, the favorable safety and tolerability profile of Bria-IMT™ plus an immune checkpoint inhibitor, the continued advancement of BriaCell’s pivotal Phase 3 Bria‑ABC study under FDA Fast Track designation, and Bria-IMT’s potential as a transformative immunotherapy for patients with metastatic breast cancer, are based on BriaCell’s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Further, certain forward-looking statements, such as those are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully under the heading “Risks and Uncertainties” in the Company’s most recent Management’s Discussion and Analysis, under the heading “Risk Factors” in the Company’s most recent Annual Information Form, and under “Risks and Uncertainties” in the Company’s other filings with the Canadian securities regulatory authorities and the U.S. Securities and Exchange Commission, all of which are available under the Company’s profiles on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov. Forward-looking statements contained in this announcement are made as of this date, and BriaCell Therapeutics Corp. undertakes no duty to update such information except as required under applicable law.

Neither the Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact Information

Company Contact:
William V. Williams, MD
President & CEO
1-888-485-6340
info@briacell.com 

Investor Relations Contact:
investors@briacell.com

Full-service, Texas-founded and headquartered financial services firm deepens commitment to the state’s growing capital markets

Parent company ticker symbol to change from TCBI to TXCP on November 9, 2026

DALLAS, Sept. 14, 2026 (GLOBE NEWSWIRE) — Texas Capital Bancshares, Inc. (NASDAQ: TCBI), the parent company of Texas Capital, today announced that it will transfer the primary listing of its common stock and its 5.75% non-cumulative perpetual preferred stock series B to the Texas Stock Exchange LLC (“TXSE”) from the Nasdaq Stock Market LLC (“Nasdaq”).

“After completing our successful transformation into the only full-service financial services firm founded and headquartered in Texas, bringing Texas Capital’s corporate listing home to the Texas Stock Exchange is the logical next step as we concurrently expand access to the global capital markets in Texas and beyond,” said Rob C. Holmes, Chairman, President & Chief Executive Officer of Texas Capital. “We are a proud early supporter of TXSE and view the launch of a world-class exchange in Texas as a landmark moment that further cements the state’s position as a premier destination for innovation and investment. TXSE has a proven leadership team, state-of-the-art trade matching technology, an enviable investor base and a shared listings approach, which will, in effect, have the issuer in a net positive cash position with the exchange.”

Texas Capital Bancshares, Inc. expects to commence trading as a TXSE-listed company upon market open on October 8, 2026, where its common and preferred stock will begin trading under the ticker symbol “TCBI” and “TCBI PRB”, respectively. Shortly thereafter on November 9, 2026, the company expects to change its ticker symbols to “TXCP” and “TXCP PRB”, respectively, marking another significant milestone in the firm’s history. The company’s common and preferred stock will continue trading on Nasdaq through market close on October 7, 2026. No action is required by stockholders in connection with the transfer.

“Texas Capital is the first home-grown, full-service financial services firm in the state of Texas, and we are proud to welcome their primary corporate listing home to the Texas Stock Exchange,” said TXSE Chairman and CEO James H. Lee. “Texas Capital has been a leader in developing capital markets in the Lone Star State, so it is fitting that they will be listed on the only national securities exchange built, headquartered, and incorporated in Texas.”

Today, Texas Capital combines deep Texas roots with a national reach, delivering a full suite of capabilities across Commercial Banking, Private Banking, Corporate Banking, Investment Banking and Treasury Solutions. The firm’s decision to list on TXSE reflects the successful completion of its transformation and represents the natural next step for a Texas-founded, Texas-headquartered institution built to serve clients across the country.

Bell Ringing
To commemorate Texas Capital Bancshares, Inc.’s move to TXSE, a closing bell ceremony is planned to be held in Dallas on November 9, 2026.

ABOUT TEXAS CAPITAL
Texas Capital Bancshares, Inc. (NASDAQ®: TCBI), a member of the Russell 2000® Index and the S&P MidCap 400®, is the parent company of Texas Capital Bank (“TCB”). Texas Capital is the collective brand name for TCB and its separate, non-bank affiliates and wholly owned subsidiaries. Texas Capital is a full-service financial services firm that delivers customized solutions to businesses, entrepreneurs and individual customers. Founded in 1998, the institution is headquartered in Dallas with offices in Austin, Fort Worth, Houston, San Antonio, Chicago, Los Angeles and New York City, and has a network of clients across the country. With the ability to service clients through their entire lifecycles, Texas Capital has established commercial banking, consumer banking, corporate and investment banking and wealth management capabilities. All services are subject to applicable laws, regulations and service terms. Deposit and lending products and services are offered by TCB. For deposit products, member FDIC. For more information, please visit texascapital.com.

Trading in securities and financial instruments, strategic advisory, and other investment banking activities are performed by TCBI Securities, Inc., doing business as Texas Capital Securities. TCBI Securities, Inc. is a member of FINRA and SIPC and has registered with the SEC and other state securities regulators as a broker dealer. TCBI Securities, Inc. is a subsidiary of TCB. All investing involves risks, including the loss of principal. Past performance does not guarantee future results. Securities and other investment products offered by TCBI Securities, Inc. are not FDIC insured, may lose value and are not bank guaranteed.

Forward Looking Statements
This communication contains “forward-looking statements” within the meaning of and pursuant to the Private Securities Litigation Reform Act of 1995 regarding, among other things, TCBI transferring its listing to the TXSE, the expected benefits from and impact of the transfer of the listing, and trading under new ticker symbols. These statements are not historical in nature and may often be identified by the use of words such as “believes,” “projects,” “expects,” “may,” “estimates,” “should,” “plans,” “targets,” “intends” “could,” “would,” “anticipates,” “potential,” “confident,” “optimistic” or the negative thereof, or other variations thereon, or comparable terminology, or by discussions of strategy, objectives, estimates, trends, guidance, expectations and future plans.

Because forward-looking statements relate to future results and occurrences, they are subject to inherent and various uncertainties, risks, and changes in circumstances that are difficult to predict, may change over time, are based on management’s expectations and assumptions at the time the statements are made and are not guarantees of future results. Numerous risks and other factors, many of which are beyond management’s control, could cause actual results to differ materially from future results expressed or implied by such forward-looking statements. While there can be no assurance that any list of risks is complete, important risks and other factors that could cause actual results to differ materially from those contemplated by forward-looking statements include, but are not limited to, operational, regulatory or technical challenges related to the TXSE-listing; and the risks and factors more fully described in TCBI’s most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and other documents and filings with the SEC. The information contained in this communication speaks only as of its date. Except to the extent required by applicable law or regulation, we disclaim any obligation to update such factors or to publicly announce the results of any revisions to any of the forward-looking statements included herein to reflect future events or developments.

CONTACT: MEDIA CONTACT
Julia Monter
julia.monter@texascapital.com

INVESTOR CONTACT
Jocelyn Kukulka
investor.relations@texascapital.com

Cineplex also Delivers Highest Summer Box Office Period in Company History

TORONTO, Sept. 14, 2026 (GLOBE NEWSWIRE) — (TSX: CGX) – Cineplex, Canada’s leading entertainment and media company, today reported August 2026 box office revenues of $98 million, the highest monthly box office performance in the Company’s history. August box office revenues doubled compared to the prior year, with Cineplex outperforming the domestic box office market during the month.

Period	2025 Box Office (i)	2026 Box Office (i)	2026 as a Percentage of 2025
July	$72,722	$72,601	100%
August	$49,087	$97,962	200%
Q3 to date	$121,809	$170,563	140%
(i) Amounts are in thousands of dollars.

Record August box office results capped off the strongest summer box office in Cineplex history, covering the period from the first Friday in May through Labour Day. Through August, third-quarter box office revenues were up 40 per cent compared to the prior year.

Driving both the record month of August and the strongest summer in Cineplex history were Spider-Man: Brand New Day and The Odyssey. Spider-Man: Brand New Day is currently the second highest-grossing release ever in Cineplex and continues to perform strongly. The Odyssey also delivered exceptional results and was a major driver of premium format attendance. Demand was particularly strong in IMAX 70MM, where Cineplex operates eight of the 41 theatres worldwide, one of the largest footprints of any exhibitor globally. Showtimes for The Odyssey continue to sell out across many of these locations.

Strong consumer demand to see these incredible films in premium formats also contributed to record guest spending. In August, approximately 54% of box office revenue came from premium experiences, and Cineplex achieved a Box Office Per Patron metric of more than $15.00. This marks the first time the Company has exceeded this milestone and highlights the continued popularity of its premium experiences.

Guest spending extended beyond the screen, with Cineplex generating the highest monthly Theatre Food Service revenue in its history. Furthermore, Cineplex’s Spider-Man: Brand New Day retail merchandise program became the largest film merchandise program in the Company’s history.

“The extraordinary response to Spider-Man: Brand New Day and The Odyssey helped deliver the highest August box office and most successful summer in Cineplex’s history,” said Ellis Jacob, President and Chief Executive Officer of Cineplex. “Canadians are choosing to experience great stories on the big screen and increasingly value experiencing those stories in a premium theatrical environment. The strength of this year’s slate, combined with a compelling lineup of highly anticipated films, including Clayface, The Hunger Games: Sunrise on the Reaping, Focker-in-Law, Hexed, Avengers: Doomsday, Dune: Part Three, and Jumanji: Open World, positions Cineplex for continued momentum as we build on a record summer.”

About Cineplex

Cineplex (TSX:CGX) is a top-tier Canadian brand that operates in the Film Entertainment and Content, Amusement and Leisure, and Media sectors. Cineplex offers a unique escape from the everyday to millions of guests through its circuit of 169 movie theatres and location-based entertainment venues. In addition to being Canada’s largest and most innovative film exhibitor, the company operates Canada’s favourite destination for ‘Eats & Entertainment’ (The Rec Room), complexes specially designed for teens and families (Playdium), and an entertainment concept that brings movies, amusement gaming, dining, and live performances together under one roof (Cineplex Junxion). It also operates successful businesses in cinema media (Cineplex Media), alternative programming (Cineplex Events) and motion picture distribution (Cineplex Pictures). Providing even more value for its guests, Cineplex is a partner in Scene+, Canada’s largest entertainment and lifestyle loyalty program.

Proudly recognized as having one of the country’s Most Admired Corporate Cultures, Cineplex employs over 10,000 people in its offices and venues across Canada. To learn more, visit Cineplex.com.

Investors:
Mahsa Rejali
Vice President, Corporate Development and Investor Relations
InvestorRelations@Cineplex.com

Media:
Michelle Saba, CPIR
Vice President, Communications
PressRoom@Cineplex.com

• Mint features a new and innovative patch pump architecture 
• Full Mint U.S. commercialization expected to begin in Q1 2027
• Manufacturing capacity expected to produce at least 1.5 million disposable Mint units during 2027
• 3D Intelligence, the Company’s next-generation insulin dosing algorithm, has been submitted to the FDA through a 510(k) application
• Expectations to commercialize 3D Intelligence in the U.S. by the end of 2026 as iLet 3D™, and at the time of full Mint launch as Mint 3D™, subject to regulatory clearance by the FDA
• Updated full year 2026 guidance

IRVINE, Calif., Sept. 14, 2026 (GLOBE NEWSWIRE) — Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced U.S. Food and Drug Administration (FDA) clearance of Mint, the Company’s patch pump featuring a transformative reusable and disposable architecture that does not require recharging, integrates with industry-leading continuous glucose monitors (CGM) and enables smartphone control for iOS and Android users. Mint is expected to meaningfully expand the Company’s addressable insulin delivery market, particularly among people with diabetes seeking a patch pump form factor.

Additionally, the Company is unveiling 3D Intelligence, its anticipated next-generation insulin dosing algorithm, which has been submitted to the FDA through a 510(k) application. 3D Intelligence is designed with three algorithm experiences intended to enable a more customizable treatment approach tailored to each user’s unique insulin requirements.

Subject to regulatory clearance by the FDA, Mint 3D and iLet 3D will represent Beta Bionics’ next-generation automated insulin delivery (AID) platforms, designed to maximize user choice through optionality in hardware and algorithm experience.

“We believe that our next-generation AID platform, consisting of Mint 3D and iLet 3D, will represent a transformational advancement for people living with diabetes, subject to regulatory clearance by the FDA,” said Sean Saint, President & CEO of Beta Bionics. “Beta Bionics puts people with diabetes at the center of everything we do, and each element of Mint 3D and iLet 3D reflects that philosophy. Delivering choice is critical to the community we serve, and that is what Mint 3D and iLet 3D are intended to offer: the choice of wearing a patch pump or tubed pump along with an algorithm experience that is uniquely suited to each individual, all with a particular focus on improving affordability through our efforts to expand access for both iLet and Mint in the pharmacy channel.”

Expectations for Full Launch of Mint in the United States

The Company expects to initiate the full commercial launch of Mint in the United States in the first quarter of 2027, ahead of its previous target, and anticipates manufacturing capacity to produce at least 1.5 million total disposable units in the full year 2027. The Company believes it may be able to exceed the 1.5 million unit target by accelerating staffing, improving efficiency through additional automation, and enhancing manufacturing yield.

Mint is expected to launch exclusively through the pharmacy channel, with approximately 40% of insured U.S. lives expected to be able to purchase it using their pharmacy benefit. The Company anticipates coverage for Mint to increase to at least 50% of insured U.S. lives within the first year of full commercialization as it leverages its market access footprint.

Mint 3D Features Expected at the Time of Full Launch in the United States*

• Transformative, two-piece reusable and disposable architecture
  • Smaller compared to the industry-leading patch pump
  • Seamless disposable patch change process with no phone re-pairing required
  • Firmware-over-the-air updates
  • Limits environmental waste
  • Three days of wear time, with an additional 12-hour grace period
  • 200-unit insulin reservoir
  • Never requires recharging
  • Waterproof with an IPX8 rating for up to 5 feet deep for 60 minutes
• Comprehensive software and digital integration
  • Powered by Beta Bionics’ 3D Intelligence algorithm*
  • Compatible with industry-leading continuous glucose monitors: Dexcom G7, Dexcom G7 15 Day, and Abbott’s FreeStyle Libre 3 Plus
  • iOS and Android smartphone controlled

*Commercialization of Mint 3D is subject to regulatory clearance. The device is currently investigational and not available for sale. Actual product specifications and features may vary.

3D Intelligence Features & Expectations for Launch in the United States*

3D Intelligence represents the next generation of Beta Bionics’ fully adaptive automated insulin delivery technology. Building on the Company’s experience with iLet and its real-world use across more than 40,000 users, 3D Intelligence is designed to give people with diabetes greater choice in how their insulin delivery algorithm responds to their individual needs.

3D Intelligence is designed to offer clinicians three selectable algorithm experiences that they can choose based on each patient’s unique insulin needs.

• Original – the algorithm currently available with iLet, with proven real-world experience across more than 40,000 users.**
• Optimized – an enhanced experience that builds on the currently available algorithm and incorporates learnings from the Company’s real-world experience with iLet.
• Conservative – an alternative experience designed to provide a more measured response when correcting high glucose levels.

Clinicians will be able to select the experience that best meets each user’s individual needs. Together, these three experiences are intended to provide greater personalization while preserving the core simplicity and automation of the currently available iLet experience.

Subject to regulatory clearance by the FDA, the 3D Intelligence insulin dosing algorithm is expected to power both iLet 3D and Mint 3D. Commercialization of iLet 3D in the United States is expected by the end of 2026, and commercialization of Mint 3D in the United States is expected simultaneous with the full Mint Iaunch in the first quarter of 2027, in each case, subject to regulatory clearance by the FDA.

*Commercialization of iLet 3D and Mint 3D is subject to regulatory clearance by the FDA. The devices are currently investigational and not available for sale. Actual product features may vary.

**Minor differences in adaptation compared to previous algorithm are not anticipated to have a significant impact on outcomes.

2026 Full Year Guidance & Key Considerations for 2027

For the full year 2026, the Company estimates total revenue of approximately $121 million to $126 million (previously $131 million to $136 million), reflecting a potential revenue deferral impact of up to $10 million in the fourth quarter of 2026 as new prospective iLet users could choose to await the launch of Mint.

• During the full year 2027, the Company expects Mint to recapture any revenue lost in the fourth quarter of 2026.

For the full year 2026, the Company reiterates its expectations for 37% to 39% of new patient starts to be reimbursed through the pharmacy channel.

• For the full year 2027, the Company expects pharmacy coverage for iLet to increase year over year, while the percentage of iLet new patient starts reimbursed through the pharmacy channel is expected to decline year over year as more pharmacy-covered individuals adopt Mint.
• With the contribution from Mint, pharmacy channel revenue as a percentage of total revenue is expected to increase in 2027 relative to the prior year.

For the full year 2026, the Company reiterates its expectations for gross margin of 58.5% to 59.5%.

• The Company expects Mint to be modestly dilutive to full year 2027 gross margin, and highly accretive to the Company’s long-term gross margin profile at scale.

About Beta Bionics

Beta Bionics, Inc. is a commercial-stage medical device company engaged in the design, development, and commercialization of innovative solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing advanced adaptive closed-loop algorithms to simplify and improve the treatment of their disease. Beta Bionics’ proprietary insulin dosing algorithm is the first FDA-cleared algorithm that autonomously determines every insulin dose and offers the potential to substantially improve overall outcomes across broad populations of PWD. To learn more, visit www.betabionics.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this press release that are not statements of historical fact are forward-looking statements. Such forward-looking statements include, without limitation, statements regarding: expectations of Beta Bionics, Inc. (the “Company”) regarding the potential clearance by the FDA, including of 3D Intelligence, and the timing thereof; the implications and potential benefits of the FDA’s clearance of Mint; the timing or certainty of full commercial launch of Mint, iLet 3D and Mint 3D in the United States and related updates; the Company’s anticipated manufacturing timeline and capacity of production of Mint at commercial launch and during 2027; the implications and potential benefits of 3D Intelligence, iLet 3D, and Mint 3D for people with diabetes; the anticipated specifications and features of 3D Intelligence and Mint 3D; the anticipated coverage for Mint at commercial launch and within the first year of commercialization; and the Company’s 2026 full year guidance and expectations for 2027 regarding estimates of revenue, including revenue deferral and revenue recapture, new patient starts reimbursed through the pharmacy channel, pharmacy channel coverage and gross margin. Words such as “believe,” “anticipate,” “plan,” “expect,” “intend,” “will,” “may,” “goal,” “potential” and similar expressions are intended to identify forward-looking statements, though not all forward-looking statements necessarily contain these identifying words. These forward-looking statements are based on the beliefs of the management of the Company as well as assumptions made by and information currently available to the Company. Such statements reflect the current views of the Company with respect to future events and are subject to known and unknown risks and uncertainties, including business, regulatory, economic and competitive risks and uncertainties about the Company, risks inherent in developing product candidates, the Company’s ability to obtain adequate financing to fund its product development and other expenses, the Company’s ability to manufacture and scale production of its products and manage its supply chain, the Company’s ability to obtain adequate reimbursement and payer coverage for its products, trends in the industry, the Company’s relationships with its existing and future collaboration partners, the legal and regulatory framework for the industry, future expenditures and the potential impacts of global macroeconomic conditions. In light of these risks and uncertainties, the events or circumstances referred to in the forward-looking statements may not occur. The actual results may vary from the anticipated results and the variations may be material. Other factors that may cause the Company’s actual results to differ from current expectations are discussed in the Company’s filings with the U.S. Securities and Exchange Commission (the “SEC”), including our Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on February 24, 2026, as updated by its Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, filed with the SEC on July 29, 2026, and other filings that Beta Bionics may make from time to time with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date this press release is given. Except as required by law, the Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Relations:
Blake Beber
Head of Investor Relations
ir@betabionics.com

Media and Public Relations:
Felicia Sanborn
Vice President of Marketing
media@betabionics.com

Source: Beta Bionics, Inc.

ATLANTA, Sept. 14, 2026 (GLOBE NEWSWIRE) — Gray Media today launches new seasons of its popular weekday programs InvestigateTV+ and Aging Untold alongside the debut of a new weekday format for the uplifting newsmagazine program The Good Side.  

InvestigateTV+ returns for its fourth season, continuing its mission of delivering solutions-oriented, in-depth investigative journalism. Lee Zurik and Tisha Powell host the award-winning program, which airs weekdays across Gray’s markets as well as several non-Gray markets, clearing in over 72% of the U.S. daily. During the 2025-26 season, InvestigateTV+ reached nearly 13 million Adults 18+ (Source: Nielsen). The InvestigateTV team was recently honored with a prestigious National Edward R. Murrow Award for excellence in journalism. The program’s ongoing strong performance demonstrates that viewers remain hungry for impactful investigative stories that uncover critical issues and provide communities with real-world solutions.

Aging Untold enters its second season, providing practical solutions for aging adults and their families. The 30-minute, unscripted conversation-style show features returning experts “Sam” Cradduck, Amy Cameron O’Rourke, Katherine Ambrose, and Dr. Rhea Rogers, who offer guidance on navigating the aging process with dignity. Following its successful first season, which premiered in March 2026 and reached over seven million viewers 18+ (Source: Nielsen), the program continues to address the growing needs of older adults and caregivers. Viewers embraced the show’s debut season, finding comfort and valuable guidance in its honest, compassionate approach to a journey that touches every family. Heading into Season 2, Aging Untold has added new non-Gray markets and is now cleared in nearly 40% of the country.

The Good Side, which originated as a highly successful weekend program, officially transitions to a Monday-through-Friday schedule. Emmy and Edward R. Murrow award-winning journalist Debra Alfarone and new co-host Graham Ulkins lead the program, bringing viewers uplifting stories from communities across the country. By moving to a daily format, The Good Side will expand its focus on stories about people making a difference, community heroes, and positive regional stories that often go unnoticed.

“We are thrilled to return such a strong weekday lineup with these three exceptional programs that inform, inspire, and empower our audiences,” said Sandy Breland, Gray’s Chief Operating Officer. “Whether delivering investigations with impact, navigating the complexities of aging, or sharing uplifting stories, Gray Media remains dedicated to high-quality programming that resonates with viewers every single day.”

Viewers can check local listings or visit investigatetv.com, aginguntold.com, and thegoodside.tv for broadcast schedules and streaming options.

About Gray Media:

Gray Media, Inc. (NYSE: GTN) is a multimedia company headquartered in Atlanta, Georgia. We are the nation’s largest owner of top-rated local television stations and digital assets. We serve 117 full-power television markets that collectively reach approximately 37% of US television households. The portfolio includes 78 markets with the top-rated television station and 101 markets with the first and/or second highest rated television station in average all-day ratings across the 116 of such markets that were measured by Nielsen in 2025. We also own the largest Telemundo Affiliate group with 46 markets and Gray Digital Media, a full-service digital agency offering national and local clients digital marketing strategies with the most advanced digital products and services. Our additional media properties include video production companies Raycom Sports, Tupelo Media Group, and PowerNation Studios, and studio production facilities Assembly Atlanta and Third Rail Studios.

Gray Contact:

Sandy Breland, Executive Vice President, Chief Operating Officer, 404-266-8333

#        #        #

Program Provides Communications and Outreach Support for Patient Advocacy Organizations Focused on Cardiovascular Diseases

Deadline for Applications is October 2, 2026

SOUTH SAN FRANCISCO, Calif., Sept. 14, 2026 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced a call for proposals for the ninth annual Cytokinetics Communications Grant Program. The program will award a number of grants to patient advocacy organizations serving the hypertrophic cardiomyopathy (HCM) and heart failure communities. The grants are intended to support increased communications, awareness building and community engagement.

“Communications is often an underfunded area of patient advocacy, despite its potential to broaden reach and strengthen impact. When organizations have the resources to communicate effectively, they can connect patients and caregivers to critical information, amplify patient voices and build stronger partnerships that drive lasting impact across the communities they serve,” said Mary Pomerantz, Cytokinetics’ Senior Director of Patient Centricity and Corporate Responsibility. “Through our Communications Grant Program, we are honored to invest in meaningful, high-impact efforts that elevate patient perspectives, foster collaboration and expand access to support and resources.”

The Cytokinetics Communications Grant Program supports patient advocacy organizations in expanding their reach, awareness and community engagement by providing resources for new or crucial communications, marketing or outreach initiatives that would otherwise be challenging to implement. Funding from the Cytokinetics Communications Grant Program may help with programming or personnel, depending on each organization’s needs. The recipients of the 2026 Cytokinetics Communications Grants were Camp Taylor and The Canadian Sudden Arrhythmia Death Syndrome (SADS) Foundation.

Eligible organizations must have nonprofit organization or registered charity status in the United States, Canada, Europe or United Kingdom and serve the patient communities in HCM or heart failure. Organizations applying for the grant are required to submit a proposal outlining communication activities that the funding would support and the potential impact of the funding. Applications will be evaluated by a committee of representatives from Cytokinetics based on the proposal’s alignment with selection criteria. More details can be found at the application portal listed below. Recipients are responsible for providing an outcomes report to Cytokinetics to measure the impact and results of the funding at the end of 2027. Applications may now be submitted at https://www.cybergrants.com/Cytokinetics/communications_grant. The deadline to apply is October 2, 2026, and the grant recipients will be announced in January 2027.

For more information on the program, including eligibility guidelines, visit http://cytokinetics.com/responsibility/grants-and-giving/.

About the Cytokinetics Communications Grant Program

For the past nine years, the Cytokinetics Communications Grant Program has supported patient advocacy organizations to help expand their reach, awareness and community engagement by providing resources for new or crucial communications, marketing or outreach initiatives that would otherwise be challenging to implement. Cytokinetics has no oversight, involvement or management of the actual projects, programs or outputs. The goal of the Communications Grant Program is to assist patient advocacy organizations by increasing resources in order to better support patient communities and bring increased disease awareness in the communities they serve.

About Cytokinetics

Cytokinetics is a specialty cardiovascular biopharmaceutical company, building on its over 25 years of pioneering scientific innovations in muscle biology, and advancing a pipeline of potential new medicines for patients suffering from diseases of cardiac muscle dysfunction. Cytokinetics’ MYQORZO^® (aficamten) is a cardiac myosin inhibitor approved in the approved in the U.S., China, European Union and United Kingdom for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). Following positive results in ACACIA-HCM, a Phase 3 clinical trial of aficamten in patients with non-obstructive HCM (nHCM), the company plans to submit a Supplemental New Drug Application in Q4 2026. Cytokinetics is also developing omecamtiv mecarbil, an investigational cardiac myosin activator for the potential treatment of patients with heart failure with severely reduced ejection fraction and ulacamten, an investigational cardiac myosin inhibitor for the potential treatment of heart failure with preserved ejection fraction, while continuing pre-clinical research and development in muscle biology.

For additional information about Cytokinetics, visit www.cytokinetics.com and follow us on X, LinkedIn, Facebook and YouTube.

Forward-Looking Statements

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the “Act”). Cytokinetics disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act’s Safe Harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to Cytokinetics’ and its partners’ research and development activities of Cytokinetics’ product candidates. Such statements are based on management’s current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to the risks related to Cytokinetics’ business outlines in Cytokinetics’ filings with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and Cytokinetics’ actual results of operations, financial condition and liquidity, and the development of the industry in which it operates, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that Cytokinetics makes in this press release speak only as of the date of this press release. Cytokinetics assumes no obligation to update its forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

CYTOKINETICS® and the CYTOKINETICS C-shaped logo are registered trademarks of Cytokinetics in the U.S. and certain other countries.

MYQORZO® is a registered trademark of Cytokinetics in the U.S., the European Union and the United Kingdom.

Contact:
Cytokinetics
Diane Weiser
Senior Vice President, Corporate Affairs
(415) 290-7757

Previously Announced Transaction with Bernhard Capital Partners Remains Expected to Close in the Fourth Quarter of 2026

RESTON, Va., Sept. 14, 2026 (GLOBE NEWSWIRE) — Bowman Consulting Group Ltd. (NASDAQ: BWMN) (“Bowman” or the “Company”), a national engineering services and program management firm, today announced the expiration of the “go-shop” period under the terms of the previously announced definitive merger agreement with entities affiliated with Bernhard Capital Partners (“Bernhard”), dated as of August 10, 2026, pursuant to which Bernhard will acquire the Company in an all-cash transaction for $43.00 per share. The “go-shop” period expired at 5:00 p.m. Eastern Time on September 13, 2026. No proposals were received prior to the expiration.

During the 35-day “go-shop” period, at the direction of the Board of Directors, the Company and its financial advisor, BofA Securities, actively solicited inquiries relating to alternative acquisition proposals from a wide range of potentially interested third parties. In total, the Company contacted 76 potentially interested parties. This process included entering into confidentiality agreements with 8 parties and providing access to certain information regarding the Company. As of the conclusion of the “go-shop” period, no party represented an “Excluded Party” (as defined in the merger agreement).

Upon expiration of the go-shop, the Company became subject to customary “no-shop” provisions that limit its and its representatives’ ability to solicit alternative acquisition proposals from third parties or to provide confidential information to third parties, subject to specific exceptions outlined in the definitive merger agreement, including customary “fiduciary out” provisions.

As previously disclosed, under the terms of the merger agreement, Bernhard will acquire Bowman in an all-cash transaction for $43.00 per share, representing an enterprise value of approximately $1.0 billion. The purchase price represents a premium of approximately 58% to Bowman’s unaffected closing share price on Friday, August 7, 2026, and a 57% premium to the Company’s 30-day volume-weighted average share price. The transaction is expected to close in the fourth quarter of calendar year 2026, subject to approval by Bowman shareholders, receipt of required regulatory approvals and the satisfaction or waiver of other customary closing conditions.

About Bowman Consulting Group Ltd.
Headquartered in Reston, Virginia, Bowman is a national engineering services firm delivering infrastructure solutions to customers who own, develop and maintain the built environment. With over 2,500 employees and 100 offices throughout the U.S., Bowman provides a variety of planning, engineering, geospatial, construction management, commissioning, environmental consulting, land procurement and other technical services to customers operating in a diverse set of regulated end markets. Bowman trades on the Nasdaq under the symbol BWMN. For more information, visit bowman.com or investors.bowman.com.

Important Information and Where to Find It

The merger transaction described in this communication (the “Merger”) will be submitted to the Company’s stockholders for their consideration and approval at a special meeting. In connection with the Merger, the Company intends to file with the Securities and Exchange Commission (the “SEC”) a preliminary proxy statement on Schedule 14A. Once the SEC completes its review of the preliminary proxy statement, a definitive proxy statement and a form of proxy card will be filed with the SEC and mailed or otherwise furnished to the Company’s stockholders. BEFORE MAKING ANY VOTING DECISION, THE COMPANY’S STOCKHOLDERS ARE URGED TO READ THE PROXY STATEMENT IN ITS ENTIRETY, WHEN IT BECOMES AVAILABLE, AND ANY OTHER DOCUMENTS TO BE FILED WITH THE SEC IN CONNECTION WITH THE MERGER OR INCORPORATED BY REFERENCE IN THE PROXY STATEMENT (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS TO THESE DOCUMENTS), IF ANY, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE MERGER AND THE PARTIES TO THE MERGER. This communication is not a substitute for the proxy statement or any other document that may be filed by the Company with the SEC or sent to its stockholders in connection with the Merger.

The Company’s investors and stockholders may obtain a free copy of the proxy statement (when available) and other documents filed by the Company with the SEC at the SEC’s website at www.sec.gov. In addition, the Company’s investors and stockholders may obtain a free copy of the documents filed with the SEC by the Company from the Company’s website at investors.bowman.com or by directing a request to the Company by e-mail to ir@bowman.com, or by telephone to (703) 464-1000.

Participants in the Solicitation

The Company and certain of its directors, executive officers and other members of management and employees may, under the rules of the SEC, be deemed to be participants in the solicitation of proxies from the Company’s stockholders in connection with the Merger and other matters to be voted on at the special meeting of the stockholders. Information regarding the Company’s directors and executive officers, including a description of their direct or indirect interests, by security holdings or otherwise, is contained in the Company’s proxy statement on Schedule 14A for the Company’s 2026 Annual Meeting of Stockholders, which was filed with the SEC on April 28, 2026 (the “2026 Annual Meeting Proxy Statement”), including under the headings “Executive and Director Compensation,” “Security Ownership of Certain Beneficial Owners and Management” and “Certain Relationships and Related Transactions.” To the extent holdings of the Company’s securities by such directors or executive officers (or the identity of such directors or executive officers) change from the amounts set forth in the 2026 Annual Meeting Proxy Statement, such information has been or will be reflected on the Initial Statements of Beneficial Ownership on Form 3 or Statements of Change in Ownership on Form 4 filed with the SEC. Additional information regarding the interests of the Company’s directors and executive officers in the Merger will be included in the proxy statement relating to the Merger when it is filed with the SEC. You may obtain free copies of these documents using the sources indicated above.

Cautionary Statement Regarding Forward-Looking Statements

This communication contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this communication that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding the Merger, including the expected timing of the closing of the Merger, the ability of the parties to complete the Merger considering the various closing conditions, the expected impacts and benefits of the Merger, the plans, strategies and prospects, both business and financial, of the Company, and any assumptions underlying any of the foregoing.

In some cases, you can identify forward-looking statements by terminology such as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,” “predict,” “potential,” “positioned,” “seek,” “should,” “target,” “will,” “would” and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Forward-looking statements are based on the Company’s current expectations and are not guarantees of future performance. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially from the Company’s current expectations.

These risks and uncertainties include risks and developments related to, among other things, (i) the completion of the proposed Merger on the anticipated terms and timing, or at all, including the parties’ ability to obtain required stockholder approval, regulatory approvals and satisfy the other conditions to the completion of the Merger, or the failure to satisfy such conditions, (ii) the effect of the announcement or pendency of the Merger on the Company’s business, operating results, financial performance, ability to retain and hire key personnel, and relationships with customers, suppliers, competitors and others, (iii) the effect of the restrictions imposed by the definitive merger agreement (the “Merger Agreement”) during the pendency of the Merger, which may (x) disrupt the Company’s current plans and business operations, (y) impact the Company’s ability to pursue certain business opportunities or strategic transactions or (z) divert management’s attention from ongoing business operations, (iv) the availability of financing for the Merger, which is not a condition to closing of the Merger, (v) the possibility that competing offers may be made, and the effect of such competing offers on the Merger and the parties’ respective rights under the Merger Agreement, (vi) the occurrence of any event, change or other circumstances that could give rise to the termination of the Merger Agreement, (vii) the fact that the Company may be required to pay a termination fee to Bernhard if the Merger Agreement is terminated in certain circumstances, (viii) litigation being instituted against the Company, Bernhard or other parties, including their respective directors, managers or officers, in connection with the Merger, which may have an unfavorable outcome, (ix) the uncertainty of the outcome of any such litigation and its effects on the parties to the Merger Agreement, (x) changes in laws, regulations, or policies, (xi) general economic conditions, nationally and globally, and their effect on the market for the Company’s services, (xii) competitive pressures and trends in the Company’s industry and its ability to successfully compete with its competitors, (xiii) the effect on the Company’s stock price if the Merger is not completed, which may decline significantly following a termination of the Merger Agreement, (xiv) potential business uncertainty during the pendency of the Merger, including changes to existing business relationships; (xv) the significant costs, fees and expenses the Company may incur in connection with the Merger, and (xvi) the effects of unknown liabilities related to the Merger on the Company.

For additional information about other factors that could cause actual results to differ materially from those described in the forward-looking statements, please refer to the Company’s periodic reports and other filings with the SEC, including risks described under the caption “Risk Factors” in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, and the Company’s Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2026, each filed with the SEC, and other filings with the SEC, which are accessible on the SEC’s website at www.sec.gov and the Company’s Investor Relations page at investors.bowman.com. The forward-looking statements included in this communication are made only as of the date hereof, and the Company disclaims any obligation to update the forward-looking statements in the future, except as required by applicable law. Forward-looking statements should be considered in light of these risks and uncertainties. Investors and others are cautioned not to place undue reliance on forward-looking statements.

No Offer or Solicitation

This communication is for informational purposes only and is not intended to, and does not, constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval, nor shall there be any issuance or sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

Contacts

Bowman Consulting Group Ltd.
Ed Hammond / David Feldman / Quinn Conway
Collected Strategies
BWMN-CS@collectedstrategies.com

Bernhard Capital Partners
Prosek Partners for Bernhard Capital Partners
pro-Bernhard@prosek.com

Program addresses approximately 54% of the $21.1 million of notes the Company has disclosed as maturing within twelve months

SCOTTSDALE, Ariz., Sept. 14, 2026 (GLOBE NEWSWIRE) — Caliber (Nasdaq: CWD), a real estate-focused alternative asset manager, today announced that it has completed the refinancing of approximately $3.4 million of its corporate promissory notes, and has executed agreements with holders of an additional approximately $9.1 million of notes granting Caliber the right, exercisable over the next six months, to retire those notes in full for approximately $7.3 million in cash. Together the two elements address approximately $12.5 million of corporate notes, including approximately $11.3 million, or approximately 54%, of the $21.1 million of unsecured corporate and convertible notes that the Company disclosed as maturing within twelve months in its most recent periodic report.

“Our noteholders funded growth capital in Caliber’s early days and assisted the Company to grow its direct ownership of its underlying funds and real estate assets, grow Managed Assets year after year, and finance corporate operations,” said Chris Loeffler, Chief Executive Officer of Caliber. “We are grateful for their capital and their trust in Caliber, and for their engagement through this process. At the program’s conclusion we expect to have all corporate notes repaid or refinanced into long-dated maturities, which we believe will strengthen the Company overall, match maturities to the underlying use of capital, and make Caliber more attractive as a real estate asset manager.”

New amortizing note – 5 years with 6% interest
Approximately $2.9 million of note principal was exchanged for new five-year notes bearing interest at 6.0% per annum and amortizing monthly in principal and interest. The weighted average interest rate on the exchanged notes was approximately 11.5%. Over the five-year term, the new notes are scheduled to pay approximately $0.46 million of interest, compared with approximately $1.7 million had the prior notes remained outstanding at their contract rates over the same period, a 73% reduction over five years.

The exchange into amortizing notes does not reduce indebtedness at closing. Principal indebtedness will be reduced on a scheduled path retiring it in full over five years. By amortizing the notes, Caliber reduced the associated note interest rate by approximately 48%, lowering interest expense on that principal by approximately $.16 million in the first year. It also raises scheduled cash debt service on that principal to approximately $0.5 million a year. Caliber accepted the higher cash requirement in exchange for the reduced interest rate and a defined path to strengthening Caliber’s balance sheet.

The notes being restructured primarily funded long-dated investments held by the Company. Replacing obligations that mature within twelve months with five-year amortizing notes, perpetual preferred equity and payoffs funded from asset-level realizations aligns the Company’s obligations with the horizon of the assets that capital was invested in.

Convertible preferred stock
Approximately $0.6 million of note principal was converted into shares of the Company’s Series AAA Convertible Preferred Stock. The Series AAA is a perpetual preferred stock instrument which carries a 12% annual, non-cumulative dividend payable quarterly, at the Company’s option, in cash or in shares of Class A common stock and is convertible into Class A common stock in three tranches at $2.50, $3.50 and $4.50 per share.

The Series AAA is treated as equity on the Company’s balance sheet because it is perpetual and carries no mandatory redemption date. The conversion reduces the Company’s debt by approximately $0.6 million, increases equity by the same amount, and removes approximately $71,000 of annual interest expense, replacing a mandatory cash interest obligation with a non-cumulative dividend the Company may elect to pay in shares rather than cash.

Together, the refinancing and the conversion remove approximately $0.2 million of annual interest expense.

What right has been secured
Holders of approximately $9.1 million of note principal have executed payoff option and standstill agreements. Under those agreements Caliber has the right, but not the obligation, to retire those notes in full satisfaction for 80% of unreturned capital, or approximately $7.3 million in cash, at any time during the six months following execution. Caliber may exercise in whole or in part. If Caliber exercises in full, the retirement would reduce corporate note obligations by approximately $9.1 million and eliminate approximately $1.0 million of additional annual interest expense, bringing the total annual reduction to approximately $1.3 million when combined with the new five-year notes.

During the six-month period, Caliber continues to pay interest to the participating holders at their existing contract rates on the full outstanding principal balance of their notes, and not on the discounted payoff amount, and those holders have agreed to forbear from exercising remedies. The agreements do not extend the stated maturity of any note. If Caliber does not exercise within the six-month period, the right to retire the notes at a discount terminates, the forbearance terminates, and the notes remain outstanding in accordance with their terms.

Caliber has not yet raised all of the cash required to exercise. The Company expects to fund any exercise from a combination of sources. Approximately $38 million of Caliber’s capital is invested alongside its investors in the real estate assets and funds the Company manages. This balance is carried in Other Assets on the Company’s balance sheet. The $38 million in capital sits within a platform holding approximately $495.6 million of Managed Capital and approximately $737.2 million of fair value assets under management as of June 30, 2026. It is not liquid and cannot be withdrawn on demand. It is returned to the parent company when an underlying asset is sold or refinanced, or through distributable cash flow from an asset, and the Company is pursuing each of those in the ordinary course of its business.

Other expected sources for note repayment include sales of real estate held directly by the Company, realization of a portion of the Company’s estimated carried interest, which the Company valued at approximately $95.7 million as of June 30, 2026, new financings and existing capital facilities. Estimated carried interest is not a receivable, is subject to the performance and disposition of the underlying assets and may never be realized.

No assurance can be given that Caliber will obtain that funding on acceptable terms, within the six-month period, or at all. If a source of funding involves the issuance of equity securities, the Company’s existing stockholders would experience dilution.

Because the payoff agreements grant Caliber an option rather than create an obligation, the Company does not expect to recognize a gain on extinguishment of debt upon execution of the agreements. A gain would be recognized if and when the Company exercises and funds a payoff, and would be measured by the difference between the carrying amount of the notes retired and the amount paid. If Caliber were to exercise in full at the amounts described above, the Company expects that gain would be approximately $1.8 million.

About Caliber (CaliberCos Inc.)

Caliber (Nasdaq: CWD) is a real estate-focused alternative asset manager with over $2.6 billion in Managed Assets and a 17-year track record investing in middle-market hospitality and multifamily real estate. The Company pairs an institutional-quality asset management platform with a boutique, hands-on investment approach focused on value creation in underserved market segments. Investors can participate in Caliber through its publicly traded equity (Nasdaq: CWD), and through its private real estate investment funds for accredited investors and financial professionals. For more information, visit caliberco.com.

Forward-Looking Statements
This press release contains “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on the Company’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section titled “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 26, 2026, and other reports filed with the SEC thereafter. Forward-looking statements contained in this announcement are made as of this date, and the Company undertakes no duty to update such information except as required under applicable law. Nothing in this press release is an offer to sell, or a solicitation of an offer to buy, any security. Caliber Tokenization Services provides technology and administrative services, and tokenization does not guarantee any outcome, including liquidity.

CONTACTS:

Caliber Investor Relations:
Ilya Grozovsky
+1 480-214-1915
Ilya@CaliberCo.com

Media Relations:
Philip Robertson
+1 917-498-4711
PRobertson@impactpartners.llc

New high-potency transdermal balm was created with professional athletes in mind and is suitable for both high-performance recovery and everyday use

LONG BEACH, Calif. and TORONTO, Sept. 14, 2026 (GLOBE NEWSWIRE) — Glass House Brands Inc. (“Glass House” or the “Company”) (CBOE CA: GLAS.A.U) (NYSE: GLAS), one of the fastest-growing, vertically-integrated cannabis companies in the U.S., today announced the launch of Mama Sue Professional Athlete Balm, the company’s first topical product launch. A high-potency cannabis topical, the balm is formulated with proprietary transdermal technology and the Company’s award-winning Jelly Fish genetics, a CBD-rich strain for deeper and faster absorption and cooling pain relief.

The Mama Sue Professional Athlete Balm is now available for sale at select licensed cannabis dispensaries throughout California.

“We spent considerable time on the development of this balm and worked directly with professional athletes to dial in this formulation. The result is a topical that has received incredible feedback,” said Kyle Kazan, Co-Founder, Chairman, and CEO of Glass House. “We are excited for California customers to access this highly anticipated balm product and look forward to eventual distribution throughout the US and the World as we continue to develop our CPG branding and distribution capabilities.”

“This is our first topical release at Glass House. We see big opportunities in this category and are excited to give consumers a product that helps safely resolve issues with everyday aches and pains,” said Hilal Tabsh, Chief Revenue Officer of Glass House. “It’s one of the strongest transdermal topicals in the California market.”

“I’m so excited to work with Glass House to develop our first topical balm,” said “Mama” Sue Taylor, founder of Mama Sue Wellness. “I believe in the power of plant medicine to help people feel better, and this balm makes it simple to apply relief right where your body needs it.”

Mama Sue Professional Athlete Balm is available now at select licensed cannabis dispensaries across California. For more information, including where to find the product, visit glasshousebrands.com or www.mamasuewellness.com.

About Mama Sue Wellness

Mama Sue Wellness creates thoughtfully formulated cannabis wellness products designed to help people feel better and live well at every age. Made with high-quality, California-grown cannabis and ethically sourced natural ingredients, each product is developed by in-house industry experts and rigorously lab-tested. Rooted in the belief that plant medicine can support healthy, active living, Mama Sue Wellness combines purposeful formulation with a commitment to quality to serve patients and consumers across California.

About Glass House Brands Inc.

Glass House is one of the fastest-growing cannabis companies in the U.S., with a dedicated focus on the California market and building leading, lasting brands to serve consumers across all segments. Whether through its portfolio of brands, which includes Glass House Farms, PLUS Products, Allswell, and Mama Sue Wellness, Glass House is committed to realizing its vision of excellence: outstanding cannabis products, produced sustainably, for the benefit of all. For more information and company updates, visit www.glasshousebrands.com.

Forward Looking Statements

This news release contains certain forward-looking information and forward-looking statements, as defined in applicable securities laws (collectively referred to herein as “forward-looking statements”). Forward-looking statements reflect current expectations or beliefs regarding future events or Glass House’s future performance or financial results. All statements other than statements of historical fact are forward-looking statements. Often, but not always, forward-looking statements can be identified by the use of words such as “plans”, “expects”, “is expected”, “budget”, “scheduled”, “estimates”, “continues”, “forecasts”, “projects”, “predicts”, “intends”, “anticipates”, “targets” or “believes”, or variations of, or the negatives of, such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “should”, “might” or “will” be taken, occur or be achieved. Forward-looking statements in this news release include, without limitation, statements regarding the completion of the proposed joint venture with Vireo and the anticipated benefits thereof. All forward-looking statements, including those herein, are qualified by this cautionary statement. Although Glass House believes that the expectations expressed in such statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in the statements. Accordingly, readers should not place undue reliance on forward-looking statements. There are certain factors that could cause actual results to differ materially from those in the forward-looking information, including those risks disclosed in the Glass House’s Annual Information Form available on SEDAR+ at www.sedarplus.ca and in Glass House’s Form 40-F available on EDGAR at www.sec.gov. For more information on Glass House, investors are encouraged to review Glass House’s public filings on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov. The forward-looking statements and financial outlooks contained in this news release speak only as of the date of this news release or as of the date or dates specified in such statements. Glass House disclaims any intention or obligation to update or revise any forward- looking information, whether as a result of new information, future events or otherwise, other than as required by law.

For further information, please contact:

Glass House Brands Inc.
Jon DeCourcey, Vice President, Head of Capital Markets
T: (781) 724-6869
E: ir@glasshousebrands.com

Investor Relations Contact:
KCSA Strategic Communications
Phil Carlson
T: 212-896-1233
E: GlassHouseIR@kcsa.com

245 Park Avenue 100% Leased

NEW YORK, Sept. 14, 2026 (GLOBE NEWSWIRE) — SL Green Realty Corp. (NYSE: SLG), Manhattan’s largest office landlord, today announced that the Company has signed 129 Manhattan office leases totaling 1,760,649 square feet to date in 2026 with a mark-to-market 15.8% higher than the previous fully escalated rents on the same spaces. The Company’s current office leasing pipeline has increased to more than 1.0 million square feet.

Notable leases signed since the second quarter of 2026 include:

• IMG Worldwide LLC signed a 5-year renewal lease for 90,202 square feet at 304 Park Avenue South. The tenant was represented by Brian Goldman, Matthew Leon and Jason Perla of Newmark together with John Mambrino and David Providenti of Savills.
• Nearwater Management LLC signed a new 8-year lease for 37,563 square feet on the entire 28^th floor at 245 Park Avenue, bringing the building to 100% leased. The tenant was represented by Alexander Chudnoff and Harrison Potter of Jones Lang LaSalle. The landlord was represented by Bruce Mosler, Harry Blair, Ron LoRusso, Justin Royce and Pierce Hance of Cushman & Wakefield.
• Greenberg Traurig LLP signed a 10.5-year expansion lease covering 33,477 square feet on the entire 33^rd floor at One Vanderbilt Avenue. This increases the tenant’s total commitment within the building to 133,365 square feet. The building remains 100% leased. The tenant was represented by Michael Monahan and Mark Ravesloot of CBRE.
• Oceansound Partners LP signed a new 5-year lease covering 32,032 square feet on all of floors 8, 22 and 23 at 450 Park Avenue. The tenant was represented by John Johnson of Savills. The landlord was represented by Paul Amrich, Neil King, Alex D’Amario, Matthew Dichter and Brooke Dewing of CBRE.

“Strong leasing momentum continues unabated with many tenants expanding and making significant capital investment to provide upscale work environments to better recruit and retain employee talent,” said Steven Durels, SL Green’s Executive Vice President, Director of Leasing and Real Property.

About SL Green
SL Green Realty Corp., Manhattan’s largest office landlord, is a fully integrated real estate investment trust, or REIT, that is focused primarily on acquiring, managing and maximizing the value of Manhattan commercial properties. As of June 30, 2026, SL Green held interests in 54 buildings totaling 30.6 million square feet, which included ownership interests in 29.2 million square feet and 1.4 million square feet securing debt and preferred equity investments, excluding fund investments, and managed 4 buildings totaling 0.9 million square feet owned by third parties.

Forward Looking Statement
This press release includes certain statements that may be deemed to be “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and are intended to be covered by the safe harbor provisions thereof. All statements, other than statements of historical facts, included in this press release that address activities, events or developments that we expect, believe or anticipate will or may occur in the future, including such matters as future capital expenditures, dividends and acquisitions (including the amount and nature thereof), development trends of the real estate industry and the New York metropolitan area markets, occupancy, business strategies, expansion and growth of our operations and other similar matters, are forward-looking statements. These forward-looking statements are based on certain assumptions and analyses made by us in light of our experience and our perception of historical trends, current conditions, expected future developments and other factors we believe are appropriate. Forward-looking statements are not guarantees of future performance and actual results or developments may differ materially, and we caution you not to place undue reliance on such statements. Forward-looking statements are generally identifiable by the use of the words “may,” “will,” “should,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” “project,” “continue,” or the negative of these words, or other similar words or terms.

Forward-looking statements contained in this press release are subject to a number of risks and uncertainties, many of which are beyond our control, that may cause our actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by forward-looking statements made by us. Factors and risks to our business that could cause actual results to differ from those contained in the forward-looking statements include risks and uncertainties described in our filings with the Securities and Exchange Commission. Except to the extent required by law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of future events, new information or otherwise.

SLG – LEAS

Press Contact
slgreen@berlinrosen.com